Corneagen Is A Leader In Ocular Tissue Provisioncommitted To Eliminating Corneal Blindness By 2040Based In Seattlewathe Company Operates Nine U Soffices And Collaborates With Over 25 Eyeorganand Tissue Banksin 2023Corneagen Achieved A Milestone By Providing Over 32 500 Sight Restoring Graftsshowcasing Its Dedication To Enhancing Corneal Care Through High Quality Donor Tissue And Surgical Advancements The Company Offers A Range Of Servicesincluding The Supply Of Corneal Grafts Processed With Advanced Techniques And Fda Approved Surgical Devices Like The Endoserter Pl And Geuder Glass Cannulacorneagen Also Focuses On Innovation In Tissue Processing Technology And Advocates For Improved Reimbursement Policies To Enhance Patient Accessadditionallyits Spin Offaurion Biotechis Developing Cell Therapy For Corneal Endothelial Diseasesupported By Significant Funding And Moving Towards Clinical Trialscorneagen Serves Ophthalmologistshospitalsand Surgical Centersensuring Rapid Tissue Delivery Across Its Extensive Global Network
